latest news releases from the newsroom
Rockwell Medical, Inc.
Rockwell Medical Technologies, Inc. Appoints Dr. James D. Cook to Scientific Advisory Board
WIXOM, Mich., June 17, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. James D. Cook, an internationally recognized expert in the field of iron, to its Scientific Advisory Board (SAB). Dr. Cook has published over 200 peer-reviewed articles on all aspects of human iron metabolism with emphasis on iron absorption, internal iron kinetics and the clinical assessment of iron status in a career spanning over 40 years. Rockwell's SAB currently advises the Company on clinical development and market preparation for its proprietary iron-maintenance product SFP, currently in Phase IIb clinical trials. Rockwell's SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval.
Teresis Media Management, Inc.
LVI Global Selects Teresis Online for In-House Video Production
SANTA ANA, Calif., June 17, 2008 (PRIME NEWSWIRE) -- Teresis Media Management Inc., the leading provider of digital video workflow and asset management technologies, today announced that its flagship solution, Teresis Online(tm), was selected by LVI Global (LVI) for in-house video production. Teresis' online monthly subscription service is helping LVI streamline and more efficiently and affordably manage its video production processes.
Power Integrations, Inc.
Power Integrations Set to Join Russell 3000 Index
SAN JOSE, Calif., June 17, 2008 (PRIME NEWSWIRE) -- Power Integrations (Nasdaq:POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, is set to join the broad-market Russell 3000(r) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted Friday on www.russell.com.
QLogic Ships Industry's First Combined Ethernet/Fibre Channel ExpressModule for Sun Blade Systems
ALISO VIEJO, Calif., June 17, 2008 (PRIME NEWSWIRE) -- QLogic Corp. (Nasdaq:QLGC), a leader in networking for storage and high performance computing (HPC), today announced that the industry's first combination 4Gb Fibre Channel/1Gb Ethernet ExpressModule is now shipping for Sun Blade(tm) 6000 and 8000 systems. The plug-and-play QEM3472 ExpressModule, available from Sun as the Sun StorageTek(tm) Dual 4 Gb Fibre Channel Dual GbE ExpressModule Host Bus Adapter, can be added or removed without powering down or opening Sun Blade systems, maintaining precious uptime. Designed by QLogic based on the PCI ExpressModule industry standard specification the innovative quad port ExpressModule doubles the number of I/O ports available to users.
QLogic Announces General Availability of World's Fastest InfiniBand HCA, Based On QLogic TrueScale ASIC Platform
DRESDEN, Germany, June 17, 2008 (PRIME NEWSWIRE) -- ISC Show -- QLogic Corp. (Nasdaq:QLGC), a leader in networking for storage and high performance computing (HPC), today announced it is now shipping in volume the highest performing InfiniBand(r) host channel adapter (HCA) in the industry, based on the QLogic(r) TrueScale(tm) ASIC platform for Double Data Rate (DDR) and Quad Data Rate (QDR) InfiniBand. The powerful new QLogic 7200 Series DDR HCAs are based on the TrueScale DDR(tm) ASIC and deliver a higher messaging rate and lower scalable latency than any competitive cluster interconnect available today. QDR adapters based on the TrueScale QDR(tm) ASIC will be available at the end of 2008. The new QLogic 7200 family of HCAs also represents the advancement of InfiniBand as a highly reliable network solution for HPC customers, with the industry's first three-year warranty backed by global service and support.
Acura Pharmaceuticals, Inc.
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
PALATINE, Ill. and BRISTOL, Tenn., June 17, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today announced positive top-line results from Acura's pivotal Phase III study, AP-ADF-105 ("Study 105"). Both strengths of Acurox(tm) Tablets met the primary pain relief endpoint compared to placebo (p=.0001, and p less than.0001). The most prevalent reported adverse events in patients receiving Acurox(tm) Tablets were nausea, vomiting, dizziness, pruritis and flushing. Study 105 was conducted under the U.S. Food and Drug Administration ("FDA") Special Protocol Assessment ("SPA") provision. Acura and King expect to submit a New Drug Application ("NDA") for Acurox(tm) Tablets to the FDA by the end of this year with a targeted indication for the relief of moderate to severe pain where the use of an immediate release, orally administered, opioid analgesic tablet is appropriate.
Aspire International, Inc.
Aspire Announces Approval From Chinese Government
TORONTO, June 17, 2008 (PRIME NEWSWIRE) -- Aspire International, Inc's ("Aspire" or the "Company") (OTCBB:APIT) wholly owned subsidiary Aspire GuangXi announced today that the Company has received the approval of a business license from the Chinese Government.